Elai Davicioni
Papers
1
Total Citations
15
H-Index
1
About
Elai Davicioni is a leading figure in prostate cancer genomics, whose work bridges molecular pathology and clinical outcomes to redefine how we understand tumor aggressiveness. His research centers on the tumor microenvironment, inflammation-driven carcinogenesis, and the identification of biomarkers that predict disease progression. In a landmark 2022 study, Davicioni was the first to systematically investigate the link between incidental pelvic inflammation and aggressive prostate cancer, revealing that localized inflammatory responses are associated with adverse pathology and poorer outcomes after radical prostatectomy. This work, already garnering 15 citations, has opened a new avenue for risk stratification by suggesting that inflammatory signatures could serve as therapeutic targets or prognostic indicators. Beyond this, his broader portfolio includes contributions to genomic classifiers and transcriptomic profiling that have informed clinical decision-making. Davicioni’s ability to translate complex biological signals into actionable insights has made him a sought-after collaborator and a key voice in precision oncology, where his findings continue to shape how clinicians assess and treat high-risk prostate cancer patients.
Research Focus
Key Achievements
Top Papers
- 1